Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24004674 | 1.00 | FFAR3 (0.45) | FFAR3CYP19A1 | |
| SCHEMBL27044680 | 1.00 | FFAR3 (0.45) | FFAR3CYP19A1 | |
| SCHEMBL28412398 | 1.00 | FFAR3 (0.45) | FFAR3CYP19A1 | |
| SCHEMBL31324041 | 1.00 | FFAR3 (0.45) | FFAR3CYP19A1 | |
| SCHEMBL23897414 | 1.00 | FFAR3 (0.45) | FFAR3CYP19A1 | |
| SCHEMBL28658467 | 1.00 | FFAR3 (0.45) | FFAR3CYP19A1 | |
| SCHEMBL24004769 | 1.00 | FFAR3 (0.45) | FFAR3CYP19A1 | |
| SCHEMBL25963527 | 0.86 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL26103315 | 0.79 | MME (0.35) | — | |
| SCHEMBL25963073 | 0.78 | FFAR3 (0.41) | FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611461-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4704904-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | Tambo, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250255970-A1 | BIOORTHOGONAL COMPOSITIONS | TAMBO INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-12296017-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| WO-2024229427-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-4458896-A2 | BIOORTHOGONAL COMPOSITIONS | Tambo, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-111093708-B | Bioorthogonal compositions | 坦伯公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3606559-B1 | BIOORTHOGONAL COMPOSITIONS | TAMBO INC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20220259254-A1 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | TAMBO, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20220168426-A1 | BIOORTHOGONAL COMPOSITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-02 | — | — | US | disclosed |
| EP-3993834-A1 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | Tambo, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114340680-A | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy | 坦博公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11253600-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-111093708-A | Bioorthogonal compositions | 坦伯公司 | 2020-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259254-A1 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | TIE1, CD74, MERTK | FFAR3 3476/4885CYP19A1 1097/4885 |
| US-12296017-B2 | Bioorthogonal compositions | TIE1, BBOX1, ST14 | FFAR3 3156/4885CYP19A1 916/4885 |
| US-20220168426-A1 | BIOORTHOGONAL COMPOSITIONS | TIE1, BBOX1, ST14 | FFAR3 3156/4885CYP19A1 916/4885 |
| US-12611461-B2 | Bioorthogonal compositions | ACVRL1, FCGR2A, CHIT1 | FFAR3 3726/4885CYP19A1 2661/4885 |
| US-11253600-B2 | Bioorthogonal compositions | TIE1, BBOX1, ST14 | FFAR3 3156/4885CYP19A1 916/4885 |
| US-20250255970-A1 | BIOORTHOGONAL COMPOSITIONS | TIE1, BBOX1, ST14 | FFAR3 3156/4885CYP19A1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.